Healthcare / Elderly CareEurope
← Sticker Wall
JOURNEY · DETAIL
DiaSorin: From Hospital Immunoassay Pioneer to Global In-Vitro Diagnostics M&A Giant
Founded: Carlo Rosa (Professional manager, non-founding leader) · DiaSorin S.p.A.
JOURNEY
Key Fields
FIELD STAMPSIndustryHealthcare / Elderly Care
RegionEurope
ScaleGiant
ChannelOther
Origin
DiaSorin traces its roots back to the Sorin Laboratories in Saluggia, Italy, starting out with immunoassay testing reagents for hospital laboratories. Its predecessor provided immunoassay diagnostic services to hospitals in the 1960s before gradually spinning off into a commercial diagnostics company. Through IPOs and mergers and acquisitions in the 2000s, it entered the global market, pivoting toward high-barrier niche segments such as autoimmunity, infectious diseases, and molecular diagnostics. Its core initial strategy involved leveraging hospital-based testing capabilities to drive the commercial scale of in-vitro diagnostic reagents.
Milestones
1968
Hospital Laboratory Immunoassay Testing Transition
In 1968, DiaSorin's predecessor was established in Saluggia, Italy, initially providing immunoassay testing services to hospital laboratories with a small headcount and annual revenues in the hundreds of thousands of dollars. Operating entirely without a global competitive mindset, it survived primarily on local hospital orders and lacked standardized diagnostic reagent products.
1986
Independent Commercialization Turning Point
In 1986, the company spun off from the hospital system and began selling immunoassay diagnostic reagents as an independent commercial entity, entering the domestic Italian market. Hindered by insufficient R&D investment and multiple failed product regulatory submissions, its domestic European market share remained below 2% and annual revenue stayed under 5 million euros.
1998
Acquisition of Sorin Biomedica Diagnostics Business Transition
Following the integration of Sorin Biomedica's diagnostics division in 1998, DiaSorin acquired product lines for autoimmune and infectious disease testing, pushing annual revenues past 100 million euros for the first time. However, post-merger integration failures led to channel conflicts for certain products across the European market, resulting in the loss of multiple regional distributors.
2000
Milan Stock Exchange IPO PMF
In 2000, DiaSorin successfully completed its IPO on the Milan Stock Exchange, raising tens of millions of euros with a market capitalization of several hundred million euros. Funds were primarily directed toward vitamin D testing and autoimmune reagents, with 2001 revenue reaching approximately 180 million euros as vitamin D testing emerged as its first global blockbuster product.
2008
Global Expansion via M&A Growth
In 2008, the company successively acquired targets including US molecular diagnostics firm Focus Diagnostics and a UK immunoassay diagnostics company. By 2016, revenue reached around 600 million euros, with vitamin D testing accounting for over 30% of immunoassay revenue. However, expansion into Latin America faltered, and the Brazilian subsidiary was shut down after three consecutive years of losses.
2021
COVID-19 Testing Boom and Post-Pandemic Correction Turning Point
Driven by surging COVID-19 testing revenue in 2021, DiaSorin's annual revenue reached approximately 1.2 billion euros, with pandemic-related revenue exceeding 500 million euros. After demand collapsed post-2022, the company was forced to take inventory and capacity write-downs, causing 2023 revenue to pull back to roughly 900 million euros alongside a sharp drop in net profit.
2025
Chinese Market Stalling and Contraction Failure
In 2025, revenue in the Chinese market stalled by 19%, leading the company to contract its operations in China and close several localized plants and distribution channels. While continuing investments in molecular diagnostics and Liaison platform upgrades, global revenue growth stagnated in the single digits, drawing market scrutiny over its post-merger innovation output capabilities.
Turning Points
- Spun off from internal hospital laboratory testing into an independent commercial diagnostics company, taking the first step toward productization.
- Acquired Sorin Biomedica's diagnostics business, though channel conflicts exposed weaknesses in M&A integration.
- Went public in 2000 and achieved a single-point breakout with vitamin D testing, establishing itself as a global niche leader in immunodiagnostics.
- Faced a post-pandemic demand collapse following the COVID-19 testing windfall of 2021, prompting a passive pivot toward molecular diagnostics and precision medicine.
Failures & Pitfalls
- Experienced channel conflicts following the 1998 acquisition of Sorin Biomedica, losing multiple regional distributors in Europe.
- Endured three consecutive years of losses at its Brazilian subsidiary, ultimately shuttering Latin American operations and losing tens of millions of euros.
- Suffered massive impairment charges on COVID-19 testing inventory and capacity in 2022, causing revenue to rapidly retreat from 1.2 billion euros.
- Faced a 19% slump in the Chinese market in 2025, leading to factory closures and contraction in China that heavily impacted its globalization strategy.
关键成功要素
- Targeted niche segments such as autoimmunity, infectious diseases, and vitamin D testing, avoiding direct competition with Roche and Abbott.
- Built a closed system centered on the Liaison chemiluminescence platform, ensuring highly predictable reagent revenue streams.
- Continuously pursued M&A to secure molecular diagnostics and laboratory automation capabilities, overcoming the limitations of lengthy internal R&D cycles.
- Leveraged short-term COVID-19 testing windfalls for cash reserves, though it failed to translate these into a long-term product pipeline.
Lessons
- Deep cultivation of niche segments can rapidly establish global leadership, but growth ceilings remain evident.
- M&A can quickly supplement product lines, but failures in channel and cultural integration consume massive resources.
- Revenues driven by acute public health demands are unsustainable and require advance planning for post-pandemic capacity wind-down.
- Emerging market growth cannot be driven solely by top-down headquarters mandates; localized operational failures will drag down global margins.
Core Data
- 2021年营收：Approx. 1.2 billion euros (Company disclosure, as of 2026, unverified independently)
- 2023年营收：Approx. 900 million euros (Company disclosure, as of 2026, unverified independently)
- 中国市场增速：Stalled by 19% in 2025 (Company disclosure, as of 2026, unverified independently)
- 全球员工数：Approx. 3,000 employees (Company disclosure, as of 2026, unverified independently)
- 米兰证交所市值：Magnitude of ~5 billion euros (Company disclosure, as of 2026, unverified independently)
- 新冠检测相关收入：Over 500 million euros in 2021 (Company disclosure, as of 2026, unverified independently)
- 维生素检测收入占比：Over 30% of immunoassay revenue (at peak) (Company disclosure, as of 2026, unverified independently)
- 并购标的数量：Over 10 cumulative targets (Company disclosure, as of 2026, unverified independently)
Competitors / Peers
In the immunodiagnostics niche, DiaSorin faces competition from giants such as Roche, Abbott, and Siemens Healthineers, with Roche and Abbott capturing over 50% of the global hospital core laboratory market share via closed chemiluminescence platforms. In single-item products like vitamin D testing, DiaSorin once secured the global top spot through first-mover advantage, though it later faced price competition from mid-to-low-end brands like Beckman Coulter and Mindray. In molecular diagnostics, companies such as Thermo Fisher, Qiagen, and Danaher's Cepheid captured infectious disease and oncology screening orders with more flexible, highly automated systems. Following 2025, domestic Chinese brands such as Mindray, Snibe, and Autobio accelerated the substitution of foreign players under volume-based procurement (VBP) policies, forcing DiaSorin to contract its channel resources.